Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901Z94" target="_blank" >RIV/61988987:17110/18:A1901Z94 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00104709 RIV/00216208:11130/18:10382706 RIV/65269705:_____/18:00069778 RIV/00843989:_____/18:E0107331 RIV/00064203:_____/18:10382706

Výsledek na webu

<a href="http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=3&SID=E6BSQJ8wb7oQLp4v83E&page=1&doc=1" target="_blank" >http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=3&SID=E6BSQJ8wb7oQLp4v83E&page=1&doc=1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00431-018-3255-2" target="_blank" >10.1007/s00431-018-3255-2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study

Popis výsledku v původním jazyce

Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r=-0.62, p=0.0001) and the initial glomerular filtration rate (r=0.36, p=0.026). Patients with C3&lt;0.825g/L needed renal replacement therapy and also had significantly more renal complications (p=0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome.

Název v anglickém jazyce

Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study

Popis výsledku anglicky

Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r=-0.62, p=0.0001) and the initial glomerular filtration rate (r=0.36, p=0.026). Patients with C3&lt;0.825g/L needed renal replacement therapy and also had significantly more renal complications (p=0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30209 - Paediatrics

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Pediatrics

ISSN

0340-6199

e-ISSN

1432-1076

Svazek periodika

177

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

1837-1844

Kód UT WoS článku

000450003400013

EID výsledku v databázi Scopus

2-s2.0-85053772049